개 아토피 피부염 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2025-2030년)

The Canine Atopic Dermatitis Market is expected to register a CAGR of 8.46% during the forecast period.

The COVID-19 pandemic led to disruption in not only the research and development activities of veterinary diseases but also disrupted the logistics supply of various essential pharmaceutical products for pets. For instance, according to an article published by Frontiers in May 2022, a study was conducted in the United Kingdom which showed that a dog's chronic illness diagnosis reduced the odds of seeking care during the pandemic, it was reportedly due to difficulties in accessing care for non-urgent issues, and lack of access to a veterinarian was a major factor behind it. Thus, the COVID-19 pandemic had a significant impact on the studied market. However, with the declining COVID-19 cases and ease of restrictions, the studied market is expected to regain its full potential over the years.

The major factors that are driving the growth of the market are the increasing pollution due to allergens, and the increase in dog adoption.

The rising adoption of dogs is a major factor driving the market growth. For instance, according to the data published by the European Pet Food Industry: Facts and Figures 2021 report, 10,300,000 dogs were reported in Germany in 2021. As per the same source, the percentage of German households owning at least one dog was 19% in 2021. This shows that the adoption of dogs was high in the country which is expected to drive market growth.

Similarly, as per the Pet Food Manufacturer's Association (PFMA), pet Population 2022 data published in 2022, it was estimated that 34.9 million pets will be there in the United Kingdom in 2022, among which 13 million will be dogs. Thus, the increasing adoption of dogs is expected to increase the demand for atopic dermatitis medications. This is further anticipated to drive market growth.

Additionally, the increasing indoor allergen pollution is also increasing the prevalence of atopic dermatitis in dogs, thus driving market growth. For instance, according to an article published by Wiley Online Library in September 2022, a study was conducted which showed that exposure to indoor air pollution increased the development of atopic dermatitis in dogs.

Moreover, the developments by key market players are expected to increase market growth. For instance, in November 2021, Vimian Group entered a partnership with Angany Inc. to develop novel vaccines for allergy and atopic dermatitis in companion animals including dogs.

Thus, the aforementioned factors such as the rising dog adoption and the increasing developments by key market players are expected to boost the market growth. However, the usage of off-label drugs is expected to hinder market growth.

Canine Atopic Dermatitis Market Trends

Monoclonal Antibody Segment Expected to Exhibit Significant Market Growth Over the Forecast Period

The monoclonal antibodies segment is expected to exhibit high market growth over the forecast period. The major attributable factors are the rising awareness of biotherapeutics and increasing product approvals. Moreover, the rising dog adoption around the world is also a major factor driving the segment growth. For instance, according to the data published by the European Pet Food Industry: Facts and Figures 2021 report in 2022, 12,000,000 dogs were reported in the United Kingdom in 2021. Also, as per the same source, the estimated percentage of United Kingdom households owning at least one dog was 27% in 2021. This shows that the adoption of dogs was significantly high in the country.

Moreover, according to the data published by the European Pet Food Industry: Facts and Figures 2021 report in 2022, 12,000,000 dogs were reported in the United Kingdom in 2021. Also, as per the same source, the estimated percentage of United Kingdom households owning at least one dog was 27% in 2021. This shows that the adoption of dogs was significantly high in the country.

Similarly, according to Der Deutsche Heimtiermarktdata updated in 2022, 47% of the households in Germany had pets in 2021, and 34.7 million dogs, cats, small animals, and ornamental birds were kept by the population as pets. Also, as per the same source, 10.3 million dogs lived in 21% of households in Germany in 2021. Thus, the rising dog adoption is also expected to boost segment growth.

Furthermore, according to an article published by Frontiers in July 2022, Cytopoint, a caninized monoclonal anti-IL-31 antibody, was found to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis, as a recent retrospective study reported that Cytopoint achieved treatment success in 87.8% of the cases with allergic dermatitis. Thus, the increasing success of various monoclonal antibodies for the treatment of atopic dermatitis in dogs is expected to boost segment growth.

Thus, the aforementioned factors such as the rising dog adoption and the increasing efficacy of monoclonal antibodies in the treatment of atopic dermatitis in dogs are expected to boost the segment growth.

North America Expected to Hold Significant Market Share During the Forecast Period

North America is expected to be a significant region for the canine atopic dermatitis market owing to increased spending in R&D activities, the high concentration of key market players, and the high rate of households with dog ownership in the region.

For instance, according to the data from the Canadian Animal Health Institute (CAHI) in September 2022, it is estimated that more than half of Canadian households (60%) own at least one dog or cat in 2022. The data also detailed that the dog population increased to 7.9 million in 2022. Thus, with a large population base of dogs, the burden of atopic dermatitis among the canine population is expected to be higher which is anticipated to drive the growth in the studied market.

In the North American region, the United States is expected to hold a significant share in the studied market as the United States has one of the highest numbers of dogs in the region coupled with high animal health expenditure and a high burden of canine atopic dermatitis cases. For instance, according to the 2021-2022 American Pet Product Association (APPA) National Pet Owners Survey, about 70% of the United States households owned a pet which is about 90.5 million homes, and dogs were among the major pets with a total population of 69 million. Further, as per the same source, pet owners spent about USD 458 for dogs for surgical vet visits, and for a routine vet, they spent USD 242 for dogs. This data shows the presence of a large dog population in the country and spending on them which is usually high as compared to other regions.

Moreover, the developments by key market players are also expected to increase the market growth. For instance, in July 2021, Virbac Corporation announced the availability of CYCLAVANCE (cyclosporine oral solution) USP MODIFIED, an oral solution for the control of atopic dermatitis in dogs in the United States.

Hence, the aforementioned factors such as the growing dog adoption, and the increasing developments by key market players are expected to boost the market growth in the region.

Canine Atopic Dermatitis Industry Overview

The canine atopic dermatitis market is moderately competitive, with a few players dominating the market. Some key players expected to dominate the canine atopic dermatitis market are Zoetis, Elanco, Virbac, Toray Industries Inc., Dechra Veterinary Products, Kindred Biosciences Inc., and Ceva among others. The companies adopt various strategies, such as mergers and acquisitions, partnerships, and collaborations, along with new product launches and research activities, to expand their market share.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Pollution Related to Allergens
  • 4.2.2 Increasing Dog Ownership
• 4.3 Market Restraints
  • 4.3.1 Usage of Off-label Drugs
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

• 5.1 By Treatment Type
  • 5.1.1 Glucocorticoids
  • 5.1.2 Immunosuppressants
  • 5.1.3 Monoclonal Antibody
  • 5.1.4 Other Treatment Types
• 5.2 By Route of Administration
  • 5.2.1 Topical
  • 5.2.2 Oral
  • 5.2.3 Injectable
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Zoetis Inc.
  • 6.1.2 Elanco
  • 6.1.3 Virbac
  • 6.1.4 Toray Industries Inc.
  • 6.1.5 Ceva
  • 6.1.6 Nextmune (Vimian)
  • 6.1.7 Dechra Veterinary Products
  • 6.1.8 Vetoquinol UK Ltd
  • 6.1.9 Phibro Animal Health Corporation
  • 6.1.10 Bioiberica SAU

7 MARKET OPPORTUNITIES AND FUTURE TRENDS